Everest Medicines Limited (1952.HK)
HKD 50.8
(3.15%)
HKD 50.8
(3.15%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -769.19 Million | -1.15 Billion | -729.93 Million | -471.89 Million | -88.65 Million | -106.96 Million |
| Net Income | -844.46 Million | -247.27 Million | -1 Billion | -5.65 Billion | -214.51 Million | -991.67 Million |
| Depreciation & Amortization | 76.77 Million | 42.77 Million | 31.12 Million | 20.39 Million | 10 Million | 5.11 Million |
| Deferred income taxes | - | - | 12.39 Million | 2.88 Million | 687 Thousand | 155 Thousand |
| Stock-based compensation | 73.42 Million | 206.49 Million | 224.98 Million | 117.27 Million | 14.94 Million | 17.81 Million |
| Change in working capital | -81.28 Million | -29.56 Million | 34.35 Million | 75.9 Million | 84.86 Million | -2.86 Million |
| Other non-cash items | -84.75 Million | -1.12 Billion | -24.06 Million | 4.96 Billion | 15.35 Million | 864.49 Million |
| Investing Cash Flow | 752.49 Million | -1.02 Billion | -975.81 Million | -519.93 Million | -47.36 Million | -406.32 Million |
| Investments in PPE | -265.95 Million | -432.74 Million | -975.81 Million | -519.93 Million | -93.27 Million | -211.86 Million |
| Acquisitions | - | - | - | - | 45.9 Million | -194.45 Million |
| Investment purchases | -3.53 Billion | -1.16 Billion | - | - | - | - |
| Sales/Maturities of investments | 2.96 Billion | - | - | - | - | - |
| Other Investing Activities | 6.19 Million | 565.3 Million | -865.86 Million | -511.33 Million | -138.72 Million | -403.42 Million |
| Financing Cash Flow | 10.1 Million | -25.31 Million | -76.5 Million | 5.63 Billion | 61.99 Million | 461.37 Million |
| Debt repayment | -8.53 Million | -30.59 Million | -23.65 Million | -19.46 Million | -8.3 Million | -458.05 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -58.7 Million | - | - | - |
| Common Stock Issuance | 29.78 Million | 5.28 Million | 5.85 Million | 3.73 Billion | - | 3.31 Million |
| Other Financing Activities | 21.84 Million | -25.31 Million | 23.65 Million | 1.92 Billion | 70.29 Million | 458.05 Million |
| Accounts receivables | -44.64 Million | -5.16 Million | -49 Thousand | - | - | -2.09 Million |
| Accounts payables | - | 5.16 Million | 49 Thousand | - | - | - |
| Inventory | -7.3 Million | -11.19 Million | -447 Thousand | - | - | - |
| Other working capital | 87.22 Million | -18.37 Million | 34.79 Million | 75.9 Million | 84.86 Million | -21.27 Million |
| Cash at beginning of period | 490.78 Million | 2.64 Billion | 4.48 Billion | 106.06 Million | 183.5 Million | 226.12 Million |
| Cash at end of period | 523.06 Million | 490.78 Million | 2.64 Billion | 4.48 Billion | 106.06 Million | 183.5 Million |
| Capital Expenditure | -265.95 Million | -432.74 Million | -975.81 Million | -519.93 Million | -93.27 Million | -211.86 Million |
| Effect of forex changes on cash | 38.86 Million | 59.83 Million | -58.8 Million | -270.99 Million | -3.41 Million | 9.3 Million |
| Net cash flow / Change in cash | 32.27 Million | -2.14 Billion | -1.84 Billion | 4.37 Billion | -77.44 Million | -42.61 Million |
| Free Cash Flow | -1.03 Billion | -1.58 Billion | -1.7 Billion | -991.82 Million | -181.93 Million | -318.83 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -316.2 Million | -316.2 Million | -844.46 Million | -210.42 Million | -210.42 Million | -211.8 Million |
| Depreciation & Amortization | - | - | 76.77 Million | 22.38 Million | 16.99 Million | 14.81 Million |
| Deferred income taxes | - | - | - | - | - | -328.4 Million |
| Stock-based compensation | - | - | 73.42 Million | 14.05 Million | 14.05 Million | 22.65 Million |
| Change in working capital | - | - | -81.28 Million | -41.3 Million | -41.3 Million | 58.94 Million |
| Other non-cash items | 316.2 Million | 316.2 Million | -84.75 Million | 51.39 Million | 56.78 Million | -105.3 Million |
| Investing Cash Flow | - | - | 752.49 Million | -70.96 Million | -70.96 Million | 447.2 Million |
| Investments in PPE | - | - | -265.95 Million | -22.9 Million | -22.9 Million | -35.76 Million |
| Acquisitions | - | - | - | - | - | 616.99 Million |
| Investment purchases | - | - | -3.53 Billion | - | - | -1.96 Billion |
| Sales/Maturities of investments | - | - | 2.96 Billion | - | - | 1.35 Billion |
| Other Investing Activities | - | - | 6.19 Million | -48.06 Million | -48.06 Million | 482.97 Million |
| Financing Cash Flow | - | - | 10.1 Million | 109.18 Million | 109.18 Million | -104.13 Million |
| Debt repayment | - | - | -8.53 Million | - | - | -240.81 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 29.78 Million | - | - | 19.18 Million |
| Other Financing Activities | - | - | 21.84 Million | 109.18 Million | 109.18 Million | -104.13 Million |
| Accounts receivables | - | - | -44.64 Million | -24.51 Million | -24.51 Million | 2.19 Million |
| Accounts payables | - | - | - | - | - | -239.03 Million |
| Inventory | - | - | -7.3 Million | -3.97 Million | -3.97 Million | 324.5 Thousand |
| Other working capital | - | - | 87.22 Million | -12.81 Million | -12.81 Million | 56.42 Million |
| Cash at beginning of period | - | - | 490.78 Million | - | - | 1.85 Billion |
| Cash at end of period | - | - | 523.06 Million | -137.84 Million | -137.84 Million | 861.7 Million |
| Capital Expenditure | - | - | -265.95 Million | -22.9 Million | -22.9 Million | -35.76 Million |
| Effect of forex changes on cash | - | - | 38.86 Million | -12.17 Million | -12.17 Million | 31.6 Million |
| Net cash flow / Change in cash | - | - | 32.27 Million | -137.84 Million | -137.84 Million | -992.35 Million |
| Free Cash Flow | - | - | -1.03 Billion | -186.79 Million | -186.79 Million | -256.46 Million |
CAST
BRIL
LKMNF
DEDI
CMTNF
IDHC